Global Antiplatelet Drugs Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 2.18 Billion |
 Market Size (Forecast Year) |
USD 4.01 Billion |
 CAGR |
% |
| Major Markets Players |
|
>全球抗血小板药物市场，按药物（阿司匹林、氯吡格雷、替格瑞洛、普拉格雷等）、适应症（心肌梗塞、经皮冠状动脉介入治疗、动脉血栓形成等）、给药途径（口服、注射）、最终用户（医院、专科诊所、家庭护理等）、分销渠道（医院药房、零售药房、网上药房等）划分 - 行业趋势和预测到 2030 年。
抗血小板药物市场分析及规模
经皮冠状动脉介入治疗数量的激增可能会推动对抗血小板药物的需求。各公司致力于发现常见抗血小板药物的新型分子靶点，这有望为行业先进的抗血小板疗法铺平道路。研究人员专注于了解口服抗血小板药物在患者体内的吸收机制，这可能有助于他们提高现有和新兴抗血小板疗法的有效性。此外，试剂租赁业务和新兴经济体的兴起为预测期内的市场参与者提供了盈利机会。
Data Bridge Market Research 分析称，抗血小板药物市场在 2022 年为 21.8 亿美元，到 2030 年可能达到 40.1 亿美元，预计在预测期内的复合年增长率为 8.15%。这表明市场价值。由于对药物的需求不断增长，“医院”在抗血小板药物市场的最终用户部分占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。
抗血小板药物市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2015-2020) |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
按药物（阿司匹林、氯吡格雷、替格瑞洛、普拉格雷等）、适应症（心肌梗塞、经皮冠状动脉介入治疗、动脉血栓形成等）、给药途径（口服、注射）、最终用户（医院、专科诊所、家庭护理等）、分销渠道（医院药房、零售药房、网上药房等） |
|
覆盖国家 |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Bayer AG (Germany), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Boehringer Ingelheim International GmbH. (Germany), Bristol-Myers Squibb Company (U.S.), Merck & Co., Inc. (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Otsuka America Pharmaceutical, Inc. (U.S.), Lilly.(U.S.), AbbVie Inc. (U.S.), Genentech, Inc. (U.S.), Baxter (U.S.), Bausch Health Companies Inc. (Canada) among others |
|
Market Opportunities |
|
Market Definition
The antiplatelet drugs market is the segment of the pharmaceutical industry that involves the research, development, manufacturing, and distribution of medications designed to prevent the formation of blood clots by inhibiting platelet aggregation. Platelets are a type of blood cell responsible for clotting, which is an essential process to prevent excessive bleeding after an injury. However, in certain medical conditions, the formation of unwanted blood clots can lead to serious health issues, such as heart attacks, strokes, and deep vein thrombosis.
Antiplatelet drugs are used to reduce the risk of blood clot formation by interfering with various pathways and mechanisms involved in platelet aggregation. These drugs are commonly prescribed to individuals with a history of cardiovascular diseases, such as atherosclerosis, angina, and previous heart attacks or strokes. They are also used for patients undergoing certain medical procedures, such as coronary artery stent placement or coronary artery bypass surgery, to prevent clotting at the site of intervention.
Global Antiplatelet Drugs Market Dynamics
Drivers
- Increasing Prevalence of Chronic Blood Diseases
The cases of chronic blood diseases are growing exponentially and will likely drive the worldwide antiplatelet drugs market. Increase in the prevalence of chronic diseases such as cardiovascular diseases is owing to drive the market. The rising incidences of cardiovascular diseases is a major factor driving the antiplatelet drugs market's growth rate. In both developed and developing economies, cardiovascular illnesses are the leading cause of death.
According to the Centers for Disease Control and Prevention (CDC), over 8,00,000 individuals in the U.S. die each year from stroke and other cardiovascular disorders.
For instance, a study by the World Health Organization (WHO) has stated that cardiovascular diseases (CVDs) account for about 31% of all patient mortality each year.
- Increasing Investment for Healthcare Infrastructure
Another significant factor influencing the growth rate of antiplatelet drugs market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness myriad fungal infections will expand the antiplatelet drugs market. Additionally, high disposable income and sedentary lifestyle of people will result in the expansion of the antiplatelet drugs market. Along with this, rising geriatric population and surge in thrombotic events will enhance the market's growth rate.
- Rising Number of Geriatric Population
Expanding geriatric population worldwide is predicted to favour antiplatelet drugs demand as this population is more prone to heart diseases. The number of persons above 65 years is projected to double in the coming years. The old age people are prone to various chronic diseases such as cardiovascular diseases, which can foster the demand for antiplatelet drugs across the globe.
According to the United Nations, there were around 382 million old age people, aged 60 years or above, across the globe in 2017 and this number is expected 2.1 billion by 2050.
Opportunity
- Increase in the Number of Research and Development Activities
Rising clinical trials and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period from 2023 to 2030.Moreover, the market's growth is fuelled by an increase in the number of research and development activities. This will provide beneficial opportunities for the antiplatelet drugs market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
The rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the antiplatelet drugs market during the forecast period from2023 to 2030.
Restraint/Challenge
On the other hand, the high cost associated with the antiplatelet drugs are expected to obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and limitations in safety, efficacy and tolerability of some antiplatelet drugs will challenge the antiplatelet drugs market. Moreover, the availability of counterfeit drugs and side effects linked with antiplatelet drugs is expected to restrain and further impede the growth rate of market during the forecast period in the forecast period of 2023 to 2030.
This antiplatelet drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the antiplatelet drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In June 2021, Alfasigma announced the approval of the European license for bentracimab from PhaseBio. Bentracimab is a novel human monoclonal antibody fragment that has been shown to reverse the antiplatelet effects of Brilinta / Brilique in previous clinical tests
Global Antiplatelet Drugs Market Scope
The antiplatelet drugs market is segmented on the basis of drug, indication, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug
- Aspirin
- Clopidogrel
- Ticagrelor
- Prasugrel
- Others
Indication
- Myocardial Infraction
- Percutaneous Coronary Interventions
- Arterial Thrombosis
- Others
Route of Administration
- Oral
- Injectable
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Antiplatelet Drugs Market Regional Analysis/Insights
The antiplatelet drugs market is analysed and market size insights and trends are provided by country, drug, indication, route of administration, end-users and distribution channel as referenced above.
抗血小板药物市场报告涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区
由于新技术的采用日益广泛，以及对特定疾病治疗的需求不断增加，北美在抗血小板药物市场占据主导地位。此外，主要关键参与者的不断增加以及医疗支出的不断增加将进一步推动该地区市场的增长率。
由于心肌梗塞病例数量激增以及该地区政府举措不断增加，预计欧洲将在 2023 年至 2030 年的预测期内实现增长。此外，医疗保健基础设施的发展将进一步推动该地区市场的增长率。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
医疗保健基础设施增长安装基础和新技术渗透
抗血小板药物市场还为您提供每个国家/地区资本设备医疗支出增长、抗血小板药物市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对抗血小板药物市场的影响的详细市场分析。数据涵盖 2010 年至 2021 年的历史时期。
竞争格局和抗血小板药物市场份额分析
抗血小板药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对抗血小板药物市场的关注有关。
抗血小板药物市场的一些主要参与者包括
- F. Hoffmann-La Roche Ltd.（瑞士）
- Mylan NV（美国）
- Teva Pharmaceutical Industries Ltd.（以色列）
- 赛诺菲（法国）
- 辉瑞公司（美国）
- 葛兰素史克公司 (英国)
- 诺华公司（瑞士）
- 太阳制药工业有限公司 (印度)
- 拜耳公司（德国）
- 阿斯利康（英国）
- 强生私人有限公司（美国）
- 勃林格殷格翰国际有限公司（德国）
- 百时美施贵宝公司 (美国)
- 默克公司（美国）
- 第一三共株式会社（日本）
- 大冢美国制药公司（美国）
- 礼来（美国）
- AbbVie Inc.（美国）
- 基因泰克公司（美国）
- 百特（美国）
- Bausch Health Companies Inc.（加拿大）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
